164 related articles for article (PubMed ID: 6189105)
1. [Results of treating lymphomas with high degree of malignancy using COPP, CHOP-Bleo and MEV protocols].
Płuzańska A; Krykowski E; Robak T; Oliskiewicz W; Polkowska E; Dowgier I; Hyjek E
Pol Tyg Lek; 1982 Sep; 37(36):1049-53. PubMed ID: 6189105
[No Abstract] [Full Text] [Related]
2. Hematologic malignancies: non-Hodgkin's lymphomas.
DeVita VT
Hosp Pract (Off Ed); 1986 Sep; 21(9):103-18. PubMed ID: 2427535
[No Abstract] [Full Text] [Related]
3. [Induction of remission in patients with non-Hodgkin lymphomas with high degree of malignancy - preliminary comparison of 2 chemotherapy programs: CHOP-B (cyclophosphamide, adriamycin, vincristine, encorton, bleomycin) and MEV-A (methotrexate, cyclophosphamide, vincristine and adriamycin)].
Walewski JA
Nowotwory; 1983; 33(3):259-65. PubMed ID: 6198637
[No Abstract] [Full Text] [Related]
4. [Lymphomas. Treatment of malignant lymphomas. Current observations and future prospects].
Klastersky J
Rev Med Brux; 1982 Apr; 3(4):223-34. PubMed ID: 6178138
[No Abstract] [Full Text] [Related]
5. [Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma].
Sampi K; Honda T; Hattori M; Takayama S
Gan To Kagaku Ryoho; 1983 May; 10(5):1266-71. PubMed ID: 6191677
[TBL] [Abstract][Full Text] [Related]
6. [Combination chemotherapy for advanced diffuse non-Hodgkin's lymphomas in relapse following local radiotherapy].
Sampi K; Honda T; Hattori M
Rinsho Hoshasen; 1983 Jun; 28(6):673-7. PubMed ID: 6688641
[No Abstract] [Full Text] [Related]
7. [Treatment of non-Hodgkin's lymphomas with CHOP-bleo. Experience in 16 patients].
González Brito G; Marsá Vilá L; Chávez MI; Batista López N; Hernández Nieto L
Sangre (Barc); 1985; 30(3):367-8. PubMed ID: 2412301
[No Abstract] [Full Text] [Related]
8. [Results of treatment of the lymphoblastic and immunoblastic malignant lymphomas using the CHOP-bleo protocol (cyclophosphamide, doxorubicin, vincristine, bleomycin and prednisolone)].
Płuzańska A; Kowalczyński M; Polkowska E; Stempczyńska J; Hyjek E
Pol Arch Med Wewn; 1982; 68(1-2):55-64. PubMed ID: 6186997
[No Abstract] [Full Text] [Related]
9. [Non-Hodgkin's lymphomas: recent achievements and therapeutic perspectives].
Bron D; Vandenheule B; Stryckmans P
Rev Med Brux; 1985 Sep; 6(7):491-5. PubMed ID: 2417298
[No Abstract] [Full Text] [Related]
10. Sequential multidrug chemotherapy (CHOP-VA-MB) in patients with high-grade non-Hodgkin's lymphoma--a 20-year follow-up.
Björkholm M; Celsing F; Johansson E;
Ann Hematol; 2006 Oct; 85(10):731-3. PubMed ID: 16838163
[No Abstract] [Full Text] [Related]
11. Evaluation of two combination chemotherapies in previously untreated non Hodgkin's lymphoma.
Somoza N; Pavlovsky S; Suárez A; Morgenfeld M; Besuschio SC; Bezares R; Quiroga Micheo E; Lein JM; De María H
Medicina (B Aires); 1981; 41 Suppl():35-43. PubMed ID: 7345350
[No Abstract] [Full Text] [Related]
12. A comparative study with COP and COP-Bleo combination chemotherapy in advanced (non-Hodgkin's) lymphomas.
Kaku K; Inoue M; Fujii S; Ishida Y; Hiroshige Y; Shinohara K; Nakashima K; Matsumoto N; Kaneko T
Nihon Ketsueki Gakkai Zasshi; 1983 Jul; 46(4):940-6. PubMed ID: 6195877
[No Abstract] [Full Text] [Related]
13. Deferral of initial therapy for advanced indolent lymphomas.
Portlock CS
Cancer Treat Rep; 1982 Mar; 66(3):417-9. PubMed ID: 7037178
[No Abstract] [Full Text] [Related]
14. Corticosteroid drugs: their role in oncological practice.
Lowenthal RM; Jestrimski KW
Med J Aust; 1986 Jan; 144(2):81-5. PubMed ID: 2417096
[No Abstract] [Full Text] [Related]
15. [Treatment of malignant lymphoma in Jichi Medical School Hospital. 3) Treatment of advanced bad-risk lymphoma with the M-CHOP regimen].
Furukawa Y; Takagi S; Tsuboyama A; Tsunoda S; Komatsu N; Takeda K; Muroi K; Ohsaka A; Miwa A; Yoshida M
Rinsho Ketsueki; 1988 Jun; 29(6):833-9. PubMed ID: 3418885
[No Abstract] [Full Text] [Related]
16. Infusions, age, and drug doses: redux.
Coleman M; Boyd DB
J Clin Oncol; 1988 Apr; 6(4):751. PubMed ID: 2451714
[No Abstract] [Full Text] [Related]
17. [Chemotherapy of non-Hodgkin lymphoma with poor prognosis].
Rupniewska ZM; Kurowska M
Pol Arch Med Wewn; 1980 Aug; 64(2):167-79. PubMed ID: 6159608
[No Abstract] [Full Text] [Related]
18. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
19. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
